ArticlePatient preference and adherence2016
Higher diversity in fungal species discriminates children with type 1 diabetes mellitus from healthy control.
Article in Patient preference and adherence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 49 citations in OpenAlex.
- Characteristics of the gut mycobiome in patients with membranous nephropathy.Scientific reports · 2026Article
- The pediatric oral mycobiome: a comprehensive review of its role in health and disease.Frontiers in cellular and infection microbiology · 2026Review
- Exploring the Gut Microbiota-Retina Axis: Implications for Health and Disease.Microorganisms · 2025Review
- Multiple low-dose radiation ameliorates type-2 diabetes mellitus via gut microbiota modulation to activate TLR4/MyD88/NF-κB pathway.BMC endocrine disorders · 2025Article
- The temporal dynamics of the gut mycobiome and its association with cardiometabolic health in a nationwide cohort of 12,641 Chinese adults.Cell reports. Medicine · 2024Article
- Neonatal Gut Mycobiome: Immunity, Diversity of Fungal Strains, and Individual and Non-Individual Factors.Life (Basel, Switzerland) · 2024Review
- Microbiota Implications in Endocrine-Related Diseases: From Development to Novel Therapeutic Approaches.Biomedicines · 2024Review
- Diabetes and gut microbiome.Frontiers in microbiology · 2024Review
- The Role of Yeasts in Human Health: A Review.Life (Basel, Switzerland) · 2023Review
- Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy.Cancers · 2022Review
- Child type 1 diabetes associated with mother vaginal bacteriome and mycobiome.Medical microbiology and immunology · 2022Article
- Temporal changes in gastrointestinal fungi and the risk of autoimmunity during early childhood: the TEDDY study.Nature communications · 2022Article
- Mycobiota composition and changes across pregnancy in patients with gestational diabetes mellitus (GDM).Scientific reports · 2022Article
- Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.Probiotics and antimicrobial proteins · 2022Article
- Environmental Factors and the Risk of Developing Type 1 Diabetes-Old Disease and New Data.Biology · 2022Review
- Infectious diseases associated with pediatric type 1 diabetes mellitus: A narrative review.Frontiers in endocrinology · 2022Review
- Gut mycobiome dysbiosis in rats showing retinal changes indicative of diabetic retinopathy.PloS one · 2022Article
- Gut Microbiota and Complications of Type-2 Diabetes.Nutrients · 2021Review
- Microbiota in Pancreatic Diseases: A Review of the Literature.Journal of clinical medicine · 2021Review
- Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features.Communications biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo conduct qualitative and quantitative assessment of yeast-like fungi in the feces of children and adolescents with type 1 diabetes mellitus (T1DM) with respect to their metabolic control and duration of the disease. MATERIALS AND
methodsThe studied materials included samples of fresh feces collected from 53 children and adolescents with T1DM. Control group included 30 age- and sex-matched healthy individuals. Medical history was taken and physical examination was conducted in the two study arms. Prevalence of the yeast-like fungi in the feces was determined as well as their amounts, species diversity, drug susceptibility, and enzymatic activity.
resultsThe yeast-like fungi were found in the samples of feces from 75.4% of T1DM patients and 70% controls. In the group of T1DM patients, no correlation was found between age (Rs=0.253, P=0.068), duration of diabetes (Rs=-0.038, P=0.787), or body mass index (Rs=0.150, P=0.432) and the amount of the yeast-like fungi isolated in the feces. Moreover, no correlation was seen between the amount of the yeast-like fungi and glycated hemoglobin (Rs=0.0324, P=0.823), systolic blood pressure (Rs=0.102, P=0.483), or diastolic blood pressure (Rs=0.271, P=0.345).
conclusionOur research has shown that children and adolescents with T1DM show higher species diversity of the yeast-like fungi, with Candida albicans being significantly less prevalent versus control subjects. Moreover, fungal species in patients with T1DM turn out to be more resistant to antifungal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.